Alzheimer's Archives

News and Trends 9 Aug 2018

Modulating the Microbiome Could Boost Vaccine Performance

Dutch scientists have found that altering a patient’s microbiome with antibiotics before a vaccination can boost the body’s resulting immune response against rotavirus infection. Rotavirus causes severe vomiting and diarrhea and largely affects children. Over 200,000 children are killed by the virus each year. The rotavirus vaccine is made of weakened strains of the rotavirus, […]

August 9, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 9 Jul 2018

Swedish Alzheimer’s Treatment Slows the Disease in Phase II Trial

BioArctic, based in Stockholm, has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial tested the antibody in 856 patients with early-stage Alzheimer’s disease with plaques of amyloid-beta protein in their brains, which is considered a common hallmark of the disease. Results taken at […]

July 9, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 25 Jun 2018

Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation

NodThera raised £28M (€32M) in a Series A round co-led by Sofinnova Partners and 5AM Ventures to develop treatments for chronic inflammation. NodThera, based in Cambridge, UK, closed a substantial Series A financing round to develop its lead small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and […]

June 25, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 Jun 2018

Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers

Update (25/06/2018): Oryzon enrolls first patients in the UK in its clinical trial testing its epigenetic Alzheimer’s drug. The company plans to enroll a total of 90 patients in Spain, France and the UK. Update (14/05/2018): Oryzon has been given approval to expand to France its Phase IIa clinical trial for an epigenetic Alzheimer’s drug. The […]

June 25, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 14 Jun 2018

Our Eyes Could Open A Window to Diagnosing Alzheimer’s and Parkinson’s Disease

Spanish researchers have developed a way to diagnose neurodegenerative diseases by analyzing eye movements. The Madrid-based research team and its spin-off company Aura Innovative Robotics have developed a diagnostic test for neurodegenerative disease that tracks a patient’s eye movements and analyzes the data using machine learning. The diagnostic test, called OSCANN Desk, is currently being […]

June 14, 2018 - 2 minutesmins - By Alexander Burik

In Depth 29 May 2018

Clinical Trials in Alzheimer’s Disease Are Failing: What Can Be Done?

With no drugs that can stop the progression of the disease and hundreds of clinical trials failing, new fields of research bring hope to people with Alzheimer’s. As the Western population ages, Alzheimer’s disease is becoming one of the biggest diseases of the 21st century. But despite the efforts of science, the FDA and EMA […]

May 29, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 May 2018

Celgene Partners With German Biotech to Develop Oncology Treatments

Evotec has entered into a collaboration with Celgene to identify new therapeutics in oncology with a focus on solid tumors. Evotec, based in Hamburg, has received an upfront payment of $65M (€55M) from US-based Celgene, one of the largest biotechs worldwide. The funding will be used to identify potential new cancer treatments with a focus on […]

May 22, 2018 - 2 minutesmins - By Alexander Burik

Startup Scout 16 Mar 2018

This Belgian Biotech Could Speed Up Diagnoses for Neurodegenerative Diseases

Today we’re in Ghent, Belgium, home to several successful biotechs, including Ablynx, to visit ADx Neurosciences. The biotech specializes in biomarker assays for the detection of neurodegenerative diseases. Mission: Founded in 2011, ADx Neurosciences focuses on the development of antibodies to detect biomarkers in the diagnosis of neurodegenerative conditions from Alzheimer’s and Parkinson’s to traumatic brain injury. The anitbodies […]

March 16, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 Mar 2018

Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed?

Roche has positive clinical data in support of starting a Phase III trial in Alzheimer’s with an antibody initially developed by MorphoSys. However, the field is full of similar approaches that have failed. Roche plans to start a Phase III study to test MorphoSys’ Alzheimer’s treatment gantenerumab later this year, after encouraging preliminary clinical results. The drug […]

March 15, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 12 Feb 2018

No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug

Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of Germany’s biggest pharma companies, Boehringer Ingelheim, has given up on the development of its Alzheimer’s drug, BI 409306, which underwent Phase II testing. The […]

February 12, 2018 - 3 minutesmins - By Alex Dale

cognitive disorders syndesi therapeutics 1

News and Trends 1 Feb 2018

New Biotech Launched to Fight Cognitive Impairment Caused by Alzheimer’s

Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer’s. Syndesi Therapeutics will use of Belgian biotech UCB’s expertise in drug discovery for neurological conditions to develop new therapies in cognitive disorders using a new […]

February 1, 2018 - 3 minutesmins - By Alex Dale

alzheimers disease acimmune andrea pfeifer 1

Interview 8 Jan 2018

Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease

Efforts to treat Alzheimer’s Disease have been hit with failure after failure in the last year or so. Andrea Pfeifer, co-founder and CEO of AC Immune, told me about how her company hopes to pull off a win. Andrea Pfeifer started out as toxicologist in oncology before she moved into entrepreneurship. She left Germany after […]

January 8, 2018 - 8 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us